Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with Osimertinib in Stage IV NSCLC
NCT05583409Not yet recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Planned start Jan 2023; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05583409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583409.